Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.
Antisense oligonucleotides (ASOs) have potential as anti-cancer agents by specifically modulating genes involved in tumorigenesis. However, little is known about ASO biodistribution and tissue pharmacokinetics (PKs) in humans, including whether sufficient delivery to target tumor tissue may be achie...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797089977889193984 |
|---|---|
| author | Saleem, A Matthews, J Ranson, M Callies, S André, V Lahn, M Dickinson, C Prenant, C Brown, G McMahon, A Talbot, D Jones, T Price, P |
| author_facet | Saleem, A Matthews, J Ranson, M Callies, S André, V Lahn, M Dickinson, C Prenant, C Brown, G McMahon, A Talbot, D Jones, T Price, P |
| author_sort | Saleem, A |
| collection | OXFORD |
| description | Antisense oligonucleotides (ASOs) have potential as anti-cancer agents by specifically modulating genes involved in tumorigenesis. However, little is known about ASO biodistribution and tissue pharmacokinetics (PKs) in humans, including whether sufficient delivery to target tumor tissue may be achieved. In this preliminary study in human subjects, we used combined positron emission and computed tomography (PET-CT) imaging and subsequent modeling analysis of acquired dynamic data, to examine the in vivo biodistribution and PK properties of LY2181308 - a second generation ASO which targets the apoptosis inhibitor protein survivin. Following radiolabeling of LY2181308 with methylated carbon-11 ([(11)C]methylated-LY2181308), micro-doses (<1mg) were administered to three patients with solid tumors enrolled in a phase I trial. Moderate uptake of [(11)C]methylated-LY2181308 was observed in tumors (mean=32.5ng*h /mL, per mg administered intravenously). Highest uptake was seen in kidney and liver and lowest uptake was seen in lung and muscle. One patient underwent repeat analysis on day 15 of multiple dose therapy, during administration of LY2181308 (750mg), when altered tissue PKs and a favorable change in biodistribution was seen. [(11)C]methylated-LY2181308 exposure increased in tumor, lung and muscle, whereas renal and hepatic exposure decreased. This suggests that biological barriers to ASO tumor uptake seen at micro-doses were overcome by therapeutic dosing. In addition, (18)F-labeled fluorodeoxyglucose (FDG) scans carried out in the same patient before and after treatment showed up to 40% decreased tumor metabolism. For the development of anti-cancer ASOs, the results provide evidence of LY2181308 tumor tissue delivery and add valuable in vivo pharmacological information. For the development of novel therapeutic agents in general, the study exemplifies the merits of applying PET imaging methodology early in clinical investigations. |
| first_indexed | 2024-03-07T03:11:50Z |
| format | Journal article |
| id | oxford-uuid:b475ec54-6fac-4d04-946d-2b4b2f576154 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:11:50Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:b475ec54-6fac-4d04-946d-2b4b2f5761542022-03-27T04:26:16ZMolecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b475ec54-6fac-4d04-946d-2b4b2f576154EnglishSymplectic Elements at Oxford2011Saleem, AMatthews, JRanson, MCallies, SAndré, VLahn, MDickinson, CPrenant, CBrown, GMcMahon, ATalbot, DJones, TPrice, PAntisense oligonucleotides (ASOs) have potential as anti-cancer agents by specifically modulating genes involved in tumorigenesis. However, little is known about ASO biodistribution and tissue pharmacokinetics (PKs) in humans, including whether sufficient delivery to target tumor tissue may be achieved. In this preliminary study in human subjects, we used combined positron emission and computed tomography (PET-CT) imaging and subsequent modeling analysis of acquired dynamic data, to examine the in vivo biodistribution and PK properties of LY2181308 - a second generation ASO which targets the apoptosis inhibitor protein survivin. Following radiolabeling of LY2181308 with methylated carbon-11 ([(11)C]methylated-LY2181308), micro-doses (<1mg) were administered to three patients with solid tumors enrolled in a phase I trial. Moderate uptake of [(11)C]methylated-LY2181308 was observed in tumors (mean=32.5ng*h /mL, per mg administered intravenously). Highest uptake was seen in kidney and liver and lowest uptake was seen in lung and muscle. One patient underwent repeat analysis on day 15 of multiple dose therapy, during administration of LY2181308 (750mg), when altered tissue PKs and a favorable change in biodistribution was seen. [(11)C]methylated-LY2181308 exposure increased in tumor, lung and muscle, whereas renal and hepatic exposure decreased. This suggests that biological barriers to ASO tumor uptake seen at micro-doses were overcome by therapeutic dosing. In addition, (18)F-labeled fluorodeoxyglucose (FDG) scans carried out in the same patient before and after treatment showed up to 40% decreased tumor metabolism. For the development of anti-cancer ASOs, the results provide evidence of LY2181308 tumor tissue delivery and add valuable in vivo pharmacological information. For the development of novel therapeutic agents in general, the study exemplifies the merits of applying PET imaging methodology early in clinical investigations. |
| spellingShingle | Saleem, A Matthews, J Ranson, M Callies, S André, V Lahn, M Dickinson, C Prenant, C Brown, G McMahon, A Talbot, D Jones, T Price, P Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title | Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title_full | Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title_fullStr | Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title_full_unstemmed | Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title_short | Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. |
| title_sort | molecular imaging and pharmacokinetic analysis of carbon 11 labeled antisense oligonucleotide ly2181308 in cancer patients |
| work_keys_str_mv | AT saleema molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT matthewsj molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT ransonm molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT calliess molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT andrev molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT lahnm molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT dickinsonc molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT prenantc molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT browng molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT mcmahona molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT talbotd molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT jonest molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients AT pricep molecularimagingandpharmacokineticanalysisofcarbon11labeledantisenseoligonucleotidely2181308incancerpatients |